Active, not recruitingNCT06422715
PTLD: Multicentric Retrospective Study
Studying Post-transplant lymphoproliferative disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Principal Investigator
- Federica Cavallo, MDEmatologia Universitaria - A.O.U. Citta della Salute e della Scienza di Torino
- Enrollment
- 241 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (21)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Ematologia, Milan, MI, Italy
- Centro Di Riferimento Oncologico Di Aviano, S.O.C. Oncologia Medica e dei Tumori Immunocorrelati, Aviano, Italy
- Azienda Ospedaliera Papa Giovanni XXIII - Ematologia, Bergamo, Italy
- A.O. UNIVERSITARIA POLICLINICO S.ORSOLA-MALPIGHI DI BOLOGNA - Istituto di Ematologia "Seragnoli", Bologna, Italy
- A.O. Spedali Civili di Brescia - Ematologia, Brescia, Italy
- Ospedale Businco - Divisione di Ematologia, Cagliari, Italy
- A.O. S. Croce e Carle - S.C. di Ematologia e Trapianto di Midollo Osseo, Cuneo, Italy
- A.O. UNIVERSITARIA CAREGGI DI FIRENZE - Unità funzionale di Ematologia, Florence, Italy
- ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia, Miano, Italy
- Istituto Scientifico San Raffaele - Unitа Linfomi - Dipartimento Oncoematologia, Milan, Italy
- AOU Maggiore della Caritа di Novara - SCDU Ematologia, Novara, Italy
- IRCCS ISTITUTO ONCOLOGICO VENETO (IOV) - Oncologia 1, Padua, Italy
- IRCCS Policlinico San Matteo - Divisione di Ematologia, Pavia, Italy
- Policlinico Universitario Campus Bio-Medico - Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapia cellulare, Roma, Italy
- Dipartimento di Medicina Traslazionale e di Precisione - Policlinico Umberto I - Università "La Sapienza" Istituto Ematologia, Roma, Italy
- +6 more locations on ClinicalTrials.gov
Collaborators
Pierre Fabre Pharma AG
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06422715 on ClinicalTrials.govOther trials for Post-transplant lymphoproliferative disease
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06723457Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaNorthwestern University
- RECRUITINGPHASE1, PHASE2NCT07368634Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationDaihong Liu
- RECRUITINGPHASE2NCT06954805Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)Jennifer Amengual
- RECRUITINGPHASE1, PHASE2NCT07438067EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell TransplantationDaihong Liu
- RECRUITINGPHASE1, PHASE2NCT06040320Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)Washington University School of Medicine
- RECRUITINGPHASE2NCT05453396Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell MalignanciesUniversity of Washington
- RECRUITINGPHASE2NCT05786040Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative DisorderTimothy Voorhees
- RECRUITINGPHASE4NCT04989491Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney AllograftUniversity Hospital, Strasbourg, France
See all trials for Post-transplant lymphoproliferative disease →